Bladder cancer battle: which chemo regimen wins before or after surgery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary tumour of the bladder * Histologically confirmed infiltrating urothelial carcinoma (epidermoid and/or glandular variants are accepted if combined with TCC) * Disease defined by a T2, T3 or T4a N0 (lymph node £ 10 mm on CT scan) M0 stadification for patients receiving neoadjuvant chemotherapy OR pT3 or pT4 OR pN+ whatever pT and M0 for patients receiving adjuvant chemotherapy * 18 ≤ age ≤ 80 years * General condition 0 or 1 as per the WHO scale * Absence of previous chemotherapy for muscle-invasive disease * Haematological function: Haemoglobin \> 11 g/dl, neutrophils ≥ 1500/mm3, platelets ≥ 100,000/mm3 * Liver function: Grade\* 0 ASAT and ALAT, grade\* 0 alkaline phosphatases, normal bilirubin * Renal function: calculated (or measured) creatinine clearance ³ 40 ml/min - --- Patients covered by a social security scheme * Patient having read the information sheet and signed the informed consent form. Exclusion Criteria: * Pure adenocarcinoma or pure epidermoid carcinoma or mixed or pure small-cell neuroendocrine carcinoma * Ventricular ejection fraction \< 50% * History of cancer in the 5 years prior to entry in the trial other than basal cell skin cancer or in situ epithelioma of the cervix * Male or female patients not agreeing to use an effective method of contraception throughout the duration of treatment and for 6 months after treatment discontinuation * Pregnant women, or female subjects liable to become pregnant or currently breast-feeding, * Patient already included in another therapeutic trial on an investigational medicinal product, * Persons deprived of their freedom or under judicial protection (including guardianship) * Unable to receive medical follow-up during the trial owing to geographical, social or psychological reasons.